Johnson & Johnson to reveal Q3 figures

Johnson & Johnson will report its third-quarter results on Tuesday 14 October. Traders are expecting revenue of $18.34 billion and earnings per share of $1.42.

Johnson's baby oil bottle
Source: Bloomberg

Johnson & Johnson is trading at $104.61. The share price is down 1.1% since the company revealed its second-quarter figures in July, when revenue increased 9.1% to $19.5 billion and EPS rose by 12.9% to $1.66, both exceeding analysts’ estimates.

The CEO Alex Gorsky stated the strong second quarter was attributable to the ‘success of new product launches’. Global pharmaceutical sales jumped 21% to $8.5 billion and this was partially due to the popularity of its new drug Olysio, which is used to treat hepatitis C. Revenues at the consumer division rose by 2.4% while the medical services unit eked out a 0.7% increase in sales. Mr Gorsky hinted at going on the acquisition trail to increase the company’s portfolio in the medical services field.

Equity analysts are very bullish on the stock. Out of the 29 recommendations, 15 are buys, 13 are holds and only one is a sell.

Over the past month the stock has been rangebound between $102-$106. The 200-day moving average of $99.25 is providing support while robust numbers could put the stock on a path to $110.

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.

Find articles by analysts